Plus and Minus IconIcon showing a plus/minus toggle, indicating that the surrounding element can be opened and closed.

Melody Smith, MD

Assistant Attending Lv. 1

Melody Smith

Lab Phone

646-888-2317

Start Year

2013

Education

University of Texas Southwestern Medical School, Dallas, Texas

Melody Smith earned her MD with Distinction in Research from the University of Texas Southwestern Medical School in Dallas, Texas in 2009 and completed  her residency in Internal Medicine at UT Southwestern Medical Center. She was a fellow in Medical Hematology & Oncology at Memorial Sloan Kettering Cancer Center from 2012 to 2015 after which she joined the Adult Bone Marrow Transplant Service

Research Interests

The focus of her research is the utilization of CD19 chimeric antigen receptor (CAR) T cells in an effort to maintain graft versus tumor activity and attenuate graft-versus-host disease (GVHD) in the treatment of CD19 hematologic malignancies. Melody works with a mouse model to analyze the mechanism whereby CD19 CAR T cells suppress GVHD. She is also investigating approaches to optimize the administration of CD19 CAR T cells. This research has the potential to benefit patients, as it would be a strategy to decrease GVHD in allogeneic hematopoietic stem cell transplant recipients.

Adoptive therapy with CD19 chimeric antigen receptor (CAR) T cells

In collaboration with Dr. Michel Sadelain, we are utilizing CD19 CAR constructs that target murine CD19, which are identical to the CD19 CAR T cells that are used in our clinical trials to treat CD19 positive hematological malignancies. These CD19 CAR T cells are engineered from donor T cells and administered in the allo-HSCT setting.

Awards

  • European Hematology Association and the American Society of Hematology Translational Research Training in Hematology (2015)
  • American Society of Bone Marrow Transplant Clinical Research Training Course (2015)

Funding

Ongoing:

  • New Investigator Award, American Society for Blood and Marrow Transplantation (ASBMT), (2016- Present)
  • Parker Institute for Cancer Immunotherapy (PICI) Pilot Grant (PI) (2017- Present)
  • Physician-Scientist Training Award, Damon Runyon Cancer Research Foundation (2017- Present)
  • Burroughs Wellcome Fund Postdoctoral Enrichment Program Award (2017- Present)
  • Robert Wood Johnson ASH-AMFDP (2018-Present)

Past:

  • NIH T32 Institutional Clinical Scholars Training Grant (2013-2015)
  • The Lymphoma Foundation¬†Mortimer J. Lacher Grant (2013-2015)
  • NIH Diversity Supplement (R01 AI 100288) (2014-2016)